Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Next steps in MCC: new targets and tacking PD-1 resistance

Paul Nghiem • 2 Jun 2021
ASCO 2021
Merkel Cell Carcinoma Skin Cancer Antibodies Checkpoint Inhibitors Ipilimumab Nivolumab Talimogene laherparepvec

Paul Nghiem, MD, PhD, University of Washington Medical Center, Seattle, WA, discusses new drug targets in merkel cell carcinoma (MCC). A wide variety of promising targets and novel agents are under investigation. For example, somatostatin analogues, bispecific T-cell engagers, transgenic T-cell receptor-based therapy, and oncolytic virotherapies are all being assessed. Prof. Nghiem emphasizes the importance of developing new drug targets for PD-1-pathway refractory MCC. There is a great need for new agents in this setting where, to date, combined ipilimumab and nivolumab has been shown as the most effective treatment option with around a 20% response rate. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

More from Paul Nghiem

Adjuvant and neoadjuvant immunotherapy in MCC
2:59
Adjuvant and neoadjuvant immunotherapy in MCC
Paul Nghiem • 3 Jun 2021
Long-term follow-up results from JAVELIN Merkel 200 and KEYNOTE-017 in MCC
2:38
Long-term follow-up results from JAVELIN Merkel 200 and KEYNOTE-017 in MCC
Paul Nghiem • 3 Jun 2021
Impact and role of radiotherapy in the management of MCC
3:43
Impact and role of radiotherapy in the management of MCC
Paul Nghiem • 14 Apr 2021
The current treatment landscape for MCC
5:25
The current treatment landscape for MCC
Paul Nghiem • 14 Apr 2021

Related Videos

BRAF/MEK inhibition prior to immunotherapy in melanoma: insights from the COWBOY trial
1:45
BRAF/MEK inhibition prior to immunotherapy in melanoma: insights from the COWBOY trial
Kalijn Bol • 31 May 2026
COWBOY trial: optimal sequencing of BRAF/MEK inhibition and immunotherapy in BRAF-mutated melanoma
1:08
COWBOY trial: optimal sequencing of BRAF/MEK inhibition and immunotherapy in BRAF-mutated melanoma
Kalijn Bol • 31 May 2026
Could induction BRAF/MEK inhibition be useful for some melanoma patients with metastases?
1:02
Could induction BRAF/MEK inhibition be useful for some melanoma patients with metastases?
Kalijn Bol • 31 May 2026
The future of personalized and off-the-shelf mRNA vaccines in melanoma
1:02
The future of personalized and off-the-shelf mRNA vaccines in melanoma
James Smithy • 31 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals